Cord blood (CB) is an alternative to other sources of stem cells for transplantation. However, the impact of including CB in the initial strategy of unrelated graft search in a cohort of patients has been the object of limited analysis. Here, we report the results of such a strategy in 91 consecutive children. Absence of mismatch was required for adult donors, and up to two mismatches were allowed for CB grafts, with a nucleated cell dose over 2.5 Â 10 7 cells/kg. A graft was found for 84 of the 85 children who remained available for a 3-month search. In all, 64 patients were transplanted, 36 with CB and 28 with bone marrow (BM). Primary graft failure, acute grade II-IV and extensive chronic graft-versus-host disease occurred in five, five and zero CB, and in three, one and two BM patients, respectively. The 3-year survival was 59% in CB and 57% in BM patients. Accepting CB as a source of stem cells offers a graft to almost every child in need of an unrelated transplantation, with a probability of survival similar to that of unrelated BM transplantation. Advantages of unrelated cord blood (CB) over unrelated bone marrow (BM) include less stringent requirements for HLA compatibility between the donor and recipient, resulting from a lower risk of graft-versus-host disease (GVHD).
donor search
Advantages of unrelated cord blood (CB) over unrelated bone marrow (BM) include less stringent requirements for HLA compatibility between the donor and recipient, resulting from a lower risk of graft-versus-host disease (GVHD).
1,2 CB viral contamination rate is very low, which may be especially important in pediatric patients who are often cytomegalovirus (CMV) and Epstein-Barr virus (EBV) negative. Further, CB units from banks are more rapidly available than BM volunteer donors from international registries. 3 Accepting CB transplant as a first-line alternative to BM transplant for patients in need for an unrelated transplantation is expected to increase the probability of finding a suitable graft. However, the results of such a search strategy have not been reported to date. It carries two major risks. First, the increase in the pool of donors may be marginal. Second, if CB transplantation outcome is worse, waiting for an unrelated BM donor may be preferable to early CB transplantation. Also, in the absence of an identified HLA-compatible BM donor, other therapeutic options are also available, such as haplo-identical grafts.
To randomize patients in a study comparing unrelated CB and BM transplantation, each patient would need a CB and a BM donor available. Conducting such a study has so far not been possible. One has thus to rely on registries or single-institution studies. Clinical reports comparing outcomes for patients undergoing unrelated CB and BM transplantation recipients point to delayed time to hematopoietic recovery, and sometimes to a higher treatmentrelated mortality. [4] [5] [6] [7] [8] [9] One pediatric registry survey demonstrated a slightly better outcome after unrelated BM transplantation when compared with CB. 8 In this survey, the mean number of CB transplantations for each center was 2.6. A single-institution pediatric study, analyzing 63 CB transplantations, reported a similar outcome after unrelated CB and BM transplantation. 9 In a landmark report, the transplant center country was shown to be a significant prognostic factor. 3 We thus hypothesize that the difference in CB transplantation experience may account for some of the discrepancies between registries and singlecenter studies. In the current study, we review our 6-year experience in unrelated graft search and transplantation in children. During this period, we used a consistent strategy for graft choice, based on the use of CB as an immediate first-line alternative to BM. We report the impact of this search strategy on graft availability. We also compare the unrelated CB and BM transplantation outcomes, using overall survival as the primary end point.
Methods

Patients
All patients referred to our transplantation program for an unrelated donor search between 1996 and 2002 were eligible for analysis of graft availability. All of the patients who were transplanted were eligible for outcome analysis. One patient, transplanted with an unrelated peripheral stem cell graft as requested by the donor's registry, was excluded from analysis, since one of the two goals of this retrospective review was the comparison of outcome following unrelated CB and BM transplantation.
HLA typing and graft selection
Formal graft searches were conducted by the Canadian Unrelated Bone Marrow Donor Registry (UBMDR) on behalf of our transplantation program. HLA-A and -B typing was performed by serology for CB and by lowresolution DNA typing for BM donors, whereas highresolution DNA typing was used for HLA-DRB1 for both. CB units were selected based on total nucleated cell dose and the degree of HLA disparity. Class I or class II disparity was judged as important. A dose of 2.5 Â 10 7 nucleated cells before thawing, per kg recipient body weight and no more than two HLA mismatches were considered to be absolute prerequisites for CB graft selection. In cases where multiple suitable HLA-matched CB units were available, the one that displayed the highest nucleated cell dose was selected. An HLA-matched BM donor was preferred over a CB donor when identified. If a CB was available and no BM donor identified within 3 months of search, transplantation was performed with CB. If a CB was found first and the transplantation considered as urgent, transplantation was performed with CB. If both BM and CB grafts were available, BM was preferred, unless the transplantation was urgent and the time to obtain the graft was judged significantly shorter for CB.
Preparative regimens and graft manipulation
Patients with leukemia were treated with total body irradiation (TBI, 1200 cGy in eight fractions), cyclophosphamide 120 mg/kg over 2 days and etoposide 40 mg/kg or alternatively busulfan 16 mg/kg in 16 fractions over 4 days, cyclophosphamide 200 mg/kg over 4 days and etoposide 40 mg/kg. Patients with ALL received, in addition to their TBI, a brain irradiation boost of 600 cGy in six fractions and a single 400 cGy fraction to the testicles. All acute leukemia (AL) patients received, after transplant, 4-12 monthly intrathecal methotrexate treatments followed by oral leucovorin rescue. Busulfan pharmacokinetics and subsequent dose adjustments to target a steady-state concentration of 1200 ng/ml were generally performed.
Fanconi anemia patients received fludarabine 35 mg/kg over 5 days and cyclophosphamide 40 mg/kg over 4 days, with a single fractionated TBI dose of 400 cGy. Hemophagocytic syndrome patients received dose-adjusted busulfan 16 mg/kg in 16 fractions over 4 days, cyclophosphamide 200 mg/kg over 4 days and VP16 40 mg/kg once. Other patients with congenital/inherited conditions were treated with dose-adjusted busulfan 16 mg/kg in 16 fractions over 4 days and cyclophosphamide 200 mg/kg over 4 days.
Red cell depletion of BM grafts was performed using the Cobe 2991 (Gambro BCT, Lakewood, CO, USA) when a major donor-recipient ABO incompatibility was identified. Grafts were not T-cell depleted. All CB units were thawed and washed using slightly modified standard procedures. 10 
GVHD prophylaxis
GVHD prophylaxis in all patients consisted of 2 mg/kg/day rabbit antithymocyte globulin (ATG, Thymoglobuline, Sangstat, Mississauga, ON, Canada) administered on days À2, À1, þ 1, þ 2 with cyclosporine A (Sandimmune, Novartis, Dorval, Quebec, Canada) given intravenously from day À3 to day þ 21, and orally thereafter (Neoral, Novartis, Dorval, Quebec, Canada). Dose adjustments were made to obtain CSA levels of 250-400 ng/ml. In the absence of GVHD, cyclosporine A was tapered weekly by 5% starting at day þ 100. Patients were given 15 mg/m 2 methotrexate on day þ 1, and 10 mg/m 2 on days þ 3, þ 6, þ 11, followed by leucovorin rescue (10 mg/m 2 ). In addition, CB recipients were treated with i.v. methylprednisolone, followed by oral prednisolone 2 mg/kg/day (tapered starting on day þ 30 by 10% weekly). The GVHD prophylaxis protocol was modified in UCB recipients during the study period, based on initial experience, and methotrexate was abrogated.
Supportive care
Standard supportive care was given to all patients according to institutional guidelines, and included ursodeoxycholic acid (15 mg/kg/day), fluconazole 5 mg/kg/day for 3-6 months, Pneumocystis carinii prophylaxis with trimethoprim-sulfamethoxazole (5 mg/kg/day 3 days per week) or monthly aerosolized pentamidine for at least 6 months. Weekly intravenous immunoglobulin (500 mg/kg) was administered from transplant to day þ 100, and then monthly for 6 months. In addition, each year during the period from October to April, monthly treatments were given of RSV hyperimmune globulin (Respigam 400 mg/kg, MedImmune, Boston, MA, USA). Weekly PCR monitoring for EBV and CMV was performed for the first 100 days following transplant and positive patients had PCR results confirmed and/or treated according to clinical status. G-CSF 5 mg/kg/day was given to CB recipients weighing over 40 kg, or if the given cell dose was inferior to 3.1 Â 10 7 nucleated cell dose/ kg. All patients had central venous line catheters and were nursed in reverse isolation under high-energy particle air filtration. All patients received standard anti-infectious, transfusional and nutritional supportive care. Broadspectrum antibiotics were initiated at the time of the first febrile episode until an absolute neutrophil count greater than 500 Â 10 9 /l was obtained. Amphotericin B was initiated if fever persisted or recurred after initiation of broad-spectrum antibiotics. Patients received irradiated, CMV-negative and filtered blood products to maintain platelet counts over 20 Â 10 9 /l, and a hemoglobin level above 70 g/l. Patients were also administered total parenteral nutrition and/or enteral feeding during the peritransplant period.
Chimerism analysis
Chimerism analysis was performed from BM samples at day 30 and from either BM or peripheral blood for later results. Donor chimerism was assessed by FISH analysis of X and Y chromosomes in cases of gender-mismatched transplants, or by genotype analysis in other patients. For the latter, peripheral blood DNA was isolated from donors and recipients using DNAzol (Invitrogene, Burlington, Ontario, Canada) and subjected to PCR amplification using the Geneprint system (Promega, Madison, WI, USA). PCR products were migrated on a polyacrylamide gel and stained with silver nitrate. Genotypes that allowed distinction between the donor and the recipient were identified.
End points and statistical analysis
Overall survival was considered as the primary end point. Engraftment was considered to have occurred when the absolute neutrophil count had reached 0.5 Â 10 9 /l for at least three consecutive days. Platelet recovery was defined as the time to achieve a platelet count of 20 Â 10 9 /l, independent of platelet transfusion for three consecutive days. Primary graft failure was defined by autologous hematopoietic recovery or absence of hematopoietic recovery at day 45 with acellular BM aspiration. Transplant-related mortality (TRM) was defined as death that occurred during a continuous CR for hematological malignancies. Relapse was defined as more than 5% blasts in the BM or presence of any leukemic cell at another site. Acute GVHD was diagnosed from clinical symptoms and/or biopsies from skin, oral mucosa, gut or liver. Grading was assigned from 0 to IV, according to standard criteria. 11 Chronic GVHD was diagnosed from clinical symptoms and/or biopsies from skin or mucosa. It was classified as limited or extensive, according to published criteria. 12 Analysis was performed using February 1, 2003 as the cutoff date for follow-up. No patient was lost to follow-up. For short-range events such as relapse and GVHD, group proportions were compared using the two-sided Fischer's exact test. The date of transplant decision was defined by the date of request for the donor's HLA confirmatory typing. Event times for survival were measured from the date of transplantation to the date of last contact or death from any cause. The probability of TRM, overall survival, time to neutrophil and platelet recovery and time from transplant decision to transplant were calculated according to the Kaplan-Meier method, and compared by the two-tailed log-rank test. The results are expressed in percentages7standard error of the mean (s.e.m.). For each of these end points, the data were censored at the time of the analysis or at the time of occurrence of a competing risk factor. These competing risk factors for each end point included death for GVHD, recurrence for TRM and death, relapse, autologous reconstitution or second transplant for neutrophil and platelet engraftment.
Results
Search strategy and results
The patient was HLA typed as soon as ALL relapse was diagnosed, or for other disease when the patient was considered eligible for transplantation. When no related donor was found, search for both unrelated donor and CB was immediately initiated. To be accepted for transplantation, a BM donor had to be HLA-matched (ie identical in low resolution for A, B and high resolution for DRB1). To be accepted, a CB graft had to have more than 2.5 Â 10 7 nucleated cells/kg before thawing, and no more than two HLA mismatches. Class I or class II disparity was judged as important. If a CB was available and no BM donor identified within 3 months of search, transplantation was performed with CB. If a CB was found first and the transplantation considered as urgent, transplantation was performed with CB. If both BM and CB grafts were available, BM was preferred, unless the transplantation was urgent and the time to obtain the stem cell graft was judged significantly shorter for CB.
Search for an unrelated donor was initiated in 91 patients. In six cases, donor search was eventually cancelled because of patient death. Five of these deaths occurred during the first month of search. An unrelated graft was identified within 3 months for 84 patients of the 85 remaining patients. Among those, 64 were transplanted. The remaining 20 patients were not transplanted, due to disease evolution. Initial search disclosed an HLA-matched unrelated BM donor in 37 of the 64 transplanted patients. Among these 37, 28 proceeded to transplant with this BM donor. In nine cases, a CB graft was preferred because of faster availability. In all, 27 patients without BM donor were transplanted with CB graft (Figure 1 ). These 36 CB grafts were obtained from 18 banks worldwide. Two CB graft and recipient pairs were HLA-matched, whereas 18 were mismatched for one HLA locus, and 16 for two loci. Most patients transplanted with BM had one or more available CB grafts, but BM was preferred. The median infused nucleated cell dose was 4. Figure 1 Results of 91 graft searches with a strategy using CB as an immediate alternative to BM.
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The median time from transplant decision to transplant was 36 days shorter in CB transplant recipients: 25 days as compared to 61 days in the BM group (Po0.0001; Figure 2 ). This difference remained unchanged when calculated for patients with malignancies only (data not shown).
Characteristics of transplanted patients
A total of 64 children were transplanted. The median age was 7.0 years (range 0.1-21.2 years). Of these, 40 were male and 24 female. The ethnic origin of patients was Caucasian for 60 (94%) of 64. One additional patient was of Caribbean and Middle-East origin each, while two were issued from mixed union (Hispanic/Caucasian and African/ Caucasian one each). In all, 50 patients had hematological malignancies, 12 had inherited syndromes and two had severe aplastic anemia. Stem cell source was CB in 36 recipients and BM in 28. Patient characteristics are detailed in Table 1 and were comparable between groups. The median age was 7.5 years (range 0.1-19.5) for CB recipients and 6.8 years (range 0.4-21.2) for BM recipients. Median recipient weight was 25.6 kg (range 3.5-95) and 23.3 kg (range 3.4-79.5), respectively. The preparative regimens included the combination of busulfan and cyclophosphamide, with or without etoposide, in 16 CB and 10 BM recipients, TBI and cyclophosphamide, with or without etoposide, in 18 CB and 16 BM recipients and other preparative regimens in two patients in each group. All recipients were given ATG. All BM recipients received cyclosporine and methotrexate as GVHD prophylaxis regimen. CB recipients received either cyclosporine and methotrexate (n ¼ 9), cyclosporine, methotrexate and steroids (n ¼ 19), or cyclosporine and steroids (n ¼ 8).
Engraftment
In all, 23 CB patients received G-CSF. The median times to neutrophil recovery were 28 and 24 days for CB and BM recipients, respectively (P ¼ 0.006). Median times to platelet recovery were 43 and 27 days for CB and BM recipients, respectively (P ¼ 0.02). The percentages (7s.e.m.) of patients having engrafted at day 30 were 6179 and 8277% in CB and BM groups, respectively (P ¼ 0.01).
Primary graft failure occurred in five CB and three BM recipients. Primary diagnoses in CB patients without engraftment were acute lymphoblastic (n ¼ 3), myeloid leukemia (n ¼ 1) and myelodysplatic syndrome (n ¼ 1). Primary diagnoses in BM patients without engraftment were Hunter's syndrome (n ¼ 1), severe combined immunodeficiency (n ¼ 1) and ALL (n ¼ 1).
Chimerism analysis
Chimerism analysis was initiated uniformly in 1998 and was available at day 30 for 44 patients (28 CB and 16 BM). In all, 21 CB patients (75%) showed more than 90% myeloid cells of donor origin. Two CB patients had between 75 and 90% donor cells, two between 50 and 75%, and three fewer than 10%. Five of these seven patients ultimately rejected their graft or experienced recurrence. Among the 16 BM patients, 14 (89%, P ¼ 0.06) had more than 90% donor cells at D30, one had ALL recurrence, and one Hunter's disease patient had an autologous hematopoietic reconstitution. At last follow-up, 16 CB patients among 17 had more than 90% donor cells. One CB patient, transplanted for Krabbe's disease, had 50% of blood nucleated cells of donor origin, with all neutrophils of donor origin. Among 13, 10 BM patients had 100% donor cells. One BM patient, transplanted for SCID, had lymphocytes of donor origin and other cells of recipient origin. Two patients presented complete autologous reconstitution, one transplanted for Hunter's disease and the second for CR2-ALL.
Four CB patients transplanted for hematological malignancies received a second transplant, three for early graft failure without recurrence and one for late recurrence, 22 months after transplantation. CB transplant was used for second transplant in three patients, 1.5, 2.2 and 25.5 months after the first graft. Two of them are currently alive. The remaining CB patient received a BM second graft as salvage therapy 3.2 months after the first graft, and is currently alive. Two BM patients received a second BM graft. One patient had experienced early graft failure after transplantation for SCID. The second had experienced early recurrence after transplantation for familial erythrophagocytic lymphohistiocytosis. This patient is currently alive (after a third transplant following disease recurrence).
Graft-versus-host disease
Grade II-IV acute GVHD occurred in five CB and one BM recipients. Grade III or IV acute GVHD occurred in four CB recipients. No BM recipient experienced grade III or IV acute GVHD. All but one were controlled with glucocorticoids. A CB patient experienced acute intestinal GVHD refractory to steroid therapy. Remission was obtained by anti-TNFa monoclonal antibodies (Schering Canada, Pointe-Claire, Quebec, Canada). No death due to GVHD occurred in either group. Limited cGVHD occurred in three CB patients. Extensive chronic GVHD (bronchiolitis obliterans and auto-immune anemia) occurred in two BM recipients. One of them currently displays complete recipient chimerism and remains in CR of his leukemia. The other died from multiple organ failure.
Outcome
The 3-year survivals were 5979% in CB group and 57710% in BM group. Kaplan-Meier estimates of TRM (7s.e.m.) at day 100 were 2778% in the CB group and 1176% in the BM group. Since this study was not randomized and was not a matched pair analysis, and did not adjust for differences between groups, no definite statistical conclusion can be drawn. This design does not allow meaningful statistical comparison. In total, 36 children were alive, 34 were in remission, one with recurrent disease and one with persistent Hunter's disease and autologous reconstitution.
Recurrence supervened in six CB patients and in four BM patients among 30 and 20 patients treated for hematological malignancies, respectively. A total of 15 CB patients and 13 BM patients died. Death was due to multiple organ failure in five CB and six BM patients, recurrence in five CB and four BM patients, infection in four CB and one BM patients, and was due to other causes in one CB and two BM patients. Infectious deaths were due to varicella virus in the BM patient and to varicella virus, adenovirus, aspergillosis and EBV in CB patients (Table 2 and Figures 3a, b) . 
Discussion
We and others have reported that one-third of the patients in need of an unrelated transplant did not have a suitable graft identified if the search was restricted to HLA-matched BM. 3, [13] [14] [15] An alternative must be found for these patients. Should this alternative be unrelated CB or haplo-identical graft? Should CB be offered as an immediate, first-line alternative or should the search for a BM donor be continued for several additional months? Here, we report the results of a strategy accepting unrelated CB as an immediate first-line alternative to BM in 91 children in need of an unrelated transplantation. A graft was found for 84 of the 85 patients who completed a 3-month search. A total of 64 were eventually transplanted. The time from decision to transplantation was 1 month shorter for CB. Survival of the 36 patients transplanted with CB was similar to that of the 28 patients transplanted with BM.
This search strategy was successful for all children except one completing the 3-month search, although a BM donor was not identified in 42% of our patients. For one child, no donor was found in 4 months. Looking at the Bone Marrow Donors Worldwide database in 2003 shows that now a suitable unrelated CB unit would have been found for all patients. The search was cancelled in five children, because of their death during the first month of search. Another patient died before 3 months of search. These data show that, currently, our search strategy is successful within 1 month in almost all children in need of an unrelated transplant. Our population of patients, being mostly (94%) Caucasian, facilitates the identification of unrelated volunteer BM donors. 16 Selective recruitment of CB donors among ethnic minorities has been shown to be successful. 17 It is unknown at this time if selective recruitment among ethnic minorities will substantially increase the chances of identifying a CB donor among patients of similar ethnicity, and the impact of HLAmismatched transplant in this population. The medianinfused nucleated cell dose was 4.3 Â 10 7 /kg in CB patients. In all, 39% of patients received fewer than 3.7 Â 10 7 /kg, a feature associated with a significantly lower chance of survival. 1 The availability of larger cell doses could therefore be of benefit even in a pediatric transplant population.
In our 6-year experience with unrelated CB transplantation, survival is similar after unrelated CB and BM transplantation. This is consistent with other singleinstitution reports, but contrasts with one registry survey. 8 This discrepancy may be attributable to a publication bias. Single institutions with successful experience with CB transplantation may be more prone to report their patients. Three other causes may explain the differences between single-center studies and registry reports. First, the number of CB transplantations performed in each center is at least 10 times higher in single-center studies. The long-term practice of CB transplantation may thus explain the better results of the single-center studies. This, rather than the location itself, may explain the differences reported between US and non-US centers. 2 Second, the policy of centers with a large CB experience is to rapidly accept a CB graft when the search for an unrelated BM seems unsuccessful. Patients undergo unrelated CB transplantation earlier in these centers. Therefore, they are probably at a lower risk than patients transplanted in centers after waiting several additional months of unsuccessful BM search before proposing CB transplantation. Third, our policy was to give a higher priority to cell dose than HLA disparity (5/6 or 4/6). Cell dose is a strong predictor of CB transplantation outcome, whereas no differences of outcome have been demonstrated between HLA 5/6 and HLA 4/6 identity.
Analysis of our study secondary end points is consistent with previous reports, supporting the reproducibility of unrelated CB transplantation results between centers. 4, 18 Neutrophil recovery was slower, and fewer patients engrafted at D30, despite the use of G-CSF. Platelet recovery was also slower. In all, 89% of BM patients had complete donor chimerism at day 30, compared to 75% in CB patients. Acute and chronic GVHD rates were low and similar, although only 6% of CB donor-recipient pairs were HLA matched, as compared to 100% of BM donorrecipient pairs. The recurrence rate and causes of death were also similar between groups. Four CB recipients and two BM recipients received a second transplant.
In summary, our results strongly support the use of unrelated CB in children as an immediate alternative to unrelated BM transplantation if there is no BM donor readily available. A similar survival when CB is chosen early, together with more rapid availability of CB, suggests that unrelated CB transplantation may be considered as a choice equivalent to that of unrelated BM transplantation.
